RethinQ 2007
NCT00132977

1 Treatments

**Studied treatment** cardiac-resynchronization therapy ICD+CRT
CRT device (Epic HF or Atlas+ HF, St. Jude Medical) with a standard right atrial, right ventricular defibrillator and left ventricular leads

**Control treatment** no cardiac-resynchronization therapy

**Concomittant treatments** -

**Age (mean), years** 59 y

**Men (%)** 65.3%

**cross over to ICD (%)** -

**cross over to medical treatment (%)** -

2 Patients

**Patients** patients with standard indication for an implantable cardioverter-defibrillator, NYHA 3, EF<35%, QRS<130ms, and evidence of mechanical dyssynchrony

**Inclusion criteria** patients with a standard indication for an implantable cardioverter–defibrillator (ischemic or nonischemic cardiomyopathy and an ejection fraction of 35% or less), NYHA class III heart failure, a QRS interval of less than 130 msec, and evidence of mechanical dyssynchrony as measured on echocardiography

**Exclusion criteria** -

**Ischaemic cause (%)** 52%

**beta-blocker use (%)** 95%

**ACE-I or ARB use (%)** 90%

**Spironolactone use (%)** -

**Blinding endpoint comittee** -

**nonischemic cardiomyopathy (%)** 48%

3 Methods

**Blinding** open
Design  Parallel groups

Centers  34

Geographical area  USA

Sizes  85/85

duration of CHD  -

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>death or nonfatal CHF events</td>
<td>-/85</td>
<td>-/85</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Heart failure hospitalizations</td>
<td>-/85</td>
<td>-/85</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>All cause death</td>
<td>5/85</td>
<td>2/85</td>
<td>2,50</td>
<td>[0,47; 13,26]</td>
</tr>
<tr>
<td>heart failure death</td>
<td>-/85</td>
<td>-/85</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>sudden cardiac death</td>
<td>-/85</td>
<td>-/85</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References